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Abstract: Point of Care (PoC) diagnostics have been the subject of considerable research over the last
few decades driven by the pressure to detect diseases quickly and effectively and reduce healthcare
costs. Herein, we demonstrate a novel, fully integrated, microfluidic amperometric enzyme-linked
immunosorbent assay (ELISA) prototype using a commercial interferon gamma release assay (IGRA) as a
model antibody binding system. Microfluidic assay chemistry was engineered to take place on Au-plated
electrodes within an assay cell on a printed circuit board (PCB)-based biosensor system. The assay cell is
linked to an electrochemical reporter cell comprising microfluidic architecture, Au working and counter
electrodes and a Ag/AgCl reference electrode, all manufactured exclusively via standard commercial
PCB fabrication processes. Assay chemistry has been optimised for microfluidic diffusion kinetics to
function under continual flow. We characterised the electrode integrity of the developed platforms
with reference to biological sampling and buffer composition and subsequently we demonstrated
concentration-dependent measurements of H2O2 depletion as resolved by existing FDA-validated
ELISA kits. Finally, we validated the assay technology in both buffer and serum and demonstrate
limits of detection comparable to high-end commercial systems with the addition of full microfluidic
assay architecture capable of returning diagnostic analyses in approximately eight minutes.
Keywords: cytokine detection; eELISA; lab-on-PCB; microfluidics; PCB biosensors; point-of-care
diagnostics
1. Introduction
Biomarker analysis is one of the cornerstones of medical evaluation and PoC diagnostics
have demonstrated the potential to become fundamental medical tools when rapid, sensitive,
and user-friendly biomarker analysis in non-laboratory environments is required. Research into PoC
devices has introduced a range of novel and optimised componentry featuring different microfluidic
integration methodologies, new smart materials, novel data analytics and various connectivity
systems [1–17]. However, such technologies are usually showcased in isolation under optimised
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laboratory conditions [18–22], and while the Affordable, Sensitive, Specific, User friendly, Robust and
Rapid, Equipment-free, and Deliverable to end-users (“ASSURED”) criteria [23] proposed by WHO
can be applied effectively to individual assay, reporter or detection components, they are most of the
times less readily met by full PoC field tools.
For example, molecular components of assay technology are often developed for electrochemical
reporter systems using expensive high quality electrodes able to function with a far higher sensitivity
than, for example, the basic elemental surfaces we employ herein. This could result in a requirement for
further assay optimisation in order to integrate with true PoC field systems. Similarly, electrochemical
detection systems appropriate for PoC analysis are often developed using purified reporter reagents
rather than fluids representative of true sample matrices, and under fluidic architecture favourable to
electrode operation rather than assay or reporter kinetics. Furthermore, complete and functional
systems are required to overcome resistance to uptake by end users, who must have complete
confidence in their equipment. Therefore, the aim to develop kits capable of detecting and processing
bio-information on-chip in the most cost- and space-effective manner still remains a challenge [9,24].
Many different methods and materials have been proposed, in order to tackle the ASSURED
criteria bottleneck. Lateral flow assays [25–29] and smartphone-based [30] colorimetric [31–33] and
electrochemical [34–36] PoC devices are only few, indicative examples of the vast work been done so far
towards PoC testing devices that can reduce detection time, increase detection accuracy and ultimately
reduce overall cost. Lab-on-PCB (LoPCB) is an alternative approach to PoC diagnostic systems that
could reduce the costs associated with complex detection architectures [37–44]. By developing effective
diagnostic systems utilising the already matured PCB technology and manufactured using standard
materials and processes could further lower the cost of the PCB-based biosensing platforms, in line
with ASSURED criteria, without sacrificing detection accuracy [45]. In mass production, the PCB-based
sensors combined with bespoke PCB-based microfluidics could reach a fabrication cost close to the
one of the undoubtedly cost-effective paper-based PoC devices (excluding the electronics unit and
the chemical reagents). Moreover, a further advantage of this approach is the ability to integrate,
if necessary, sample and reagent processing, assay chemistry, microfluidics, sensing architecture
(e.g., electrochemical cells) and bespoke circuitry all at the surface of the PCB in a monolithic manner.
Such integration inevitably favors the development of PoC platforms with smaller footprint and
consequently development cost [46]. Combining both biochemistry and electronic biosensing on the
same sensing platform may also reduce noise interference due to connectivity issues which could
increase the signal-to-noise ratio (SNR) of the measurement [47].
In this work, we demonstrate a complete LoPCB biosensor platform with bespoke in-line assay
cells, electrochemical cells and full microfluidic architecture that significantly builds on previous,
proof-of-concept static LoPCB platforms [48–51]. While concepts and philosophies are, in general,
consistent with the basic principles of LoPCB systems [37,38,46,49,50], the implemented system
demonstrated herein utilises a novel system architecture and an entirely different electrochemical
treatment, illustrating a system and electrochemical reaction tailored for ELISA protocols. The assay
process is conducted under precisely controlled flow. Amperometric detection is performed using
a bespoke, multi-channel, custom-made high-performance bioinstrumentation platform [50,52].
We exploit inexpensive substrates fabricated by our industrial partner (Newbury Electronics Ltd.,
Newbury, UK) using standard, mature commercial production techniques [46,53,54].
We demonstrate full assay chemistry, adapted from a commercial IGRA (R + D Systems,
Minneapolis, MN, USA), occurring in bespoke microfluidic assay cells at an Au surface. The system
is comprised of assay cells and electrochemical detection cells linked microfluidically. The target
antigen is captured from the sample in concentration-dependant manner and subsequently horseradish
peroxidase enzyme (HRP) is localised according to captured analyte concentration via a second primary
antibody of alternative epitope. Reporter fluid 3,3′,5,5′-tetramethylbenzidine (TMB) is converted
from substrate to product by the HRP at a rate determined by the concentration of localised HRP,
and delivered to an integrated electrochemical cell. H2O2, as the enzyme co-factor, is consumed at a
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rate commensurate to TMB conversion. In the electrochemical cell amperometric analysis occurs at
Au working and counter electrodes. We report system performance comparable to current industry
standard colorimetric analyses and other indicative portable IFNγ detection systems.
The basic model assay is a commercially available IFNγ ELISA from R + D Biosystems, the only
major adaptation being the expression of the primary capture antibody in cysteinylated ScFv format.
IFNγ is a pro-inflammatory cytokine with a central role in innate and acquired immunity. In the clinical
laboratory IGRAs are used routinely in at risk populations to diagnose latent TB infection (LTBI) [55].
The presented assay boards can process eight unique channels (while electronics kit can support up to
16 simultaneous measurements), allowing us to run eight distinct assays and appropriate controls at
once on a single assay board, for demonstrating the parallel interrogation of full diagnostic suites of
biomarkers in a single process.
2. Materials and Methods
2.1. TMB Detection
TMB was prepared by adding one TMB tablet (T5525, Sigma Aldrich, St. Louis, MO, USA) to
10 mL deionised water and 5 µL 30% (by volume) H2O2. The reagent was centrifuged at 16,000 RCF
for 30 min to remove particulates and decanted to a clean tube.
2.2. Assay-Incubated
Assays were performed in bespoke measurement cells at the PCB surface. Au assay surfaces were
used to localise cysteinylated Fab’ antibodies via covalent thiol linkage. Fab’ antibodies were prepared
at a concentration of 40 µg/mL in PBS and 100 µL incubated overnight in each assay cell at 4 ◦C. Assay
wells were rinsed twice with PBS and 500 µL of 1% BSA (W:V) in PBS introduced to each well to block
exposed hydrophobic surfaces. Blocking was allowed to progress for 2 h at room temperature (RT).
Assay cells were rinsed twice with PBST (1 × PBS, 0.05% tween20-by volume) and titrated IFNγ flow
was initiated. The IFNγ titration was prepared in log2 dilution in PBS across 8 assay points from a top
concentration of 2 ng/mL. IFNγ samples were incubated at RT for 40 min. Cells were washed twice
with PBST and once with PBS. Biotinylated detection antibody (R + D Biosystems) was prepared at
200 ng/mL in PBS and added to each cell. Incubations were allowed to progress for 40 min at RT. Cells
were washed twice with PBST and once with PBS. Streptavidin-HRP was prepared in PBS at a dilution
of 1:20 from the R + D Biosystems kit stock (no data provided for concentration). Streptavidin-HRP
working dilution was added to each cell and incubated for 15 min at RT. Cells were washed twice
with PBST and once with PBS. TMB substrate was prepared using stock tablets (T5525, Sigma-Aldrich)
dissolved in 10 mL of deionised water containing 5 µL 30% (by volume) H2O2. TMB was flowed
directly across the assay surface to the electrochemical detection cell, or incubated at the assay surface
(as indicated in the text). Electrochemical measurements were taken in the electrochemical cell region of
the assay board. Electrochemical cells consist of three Au surface electrodes and an Ag/AgCl reference
electrode. Amperometric measurements were taken using the described in-house electronic control
board providing a stable reference electrode bias of + 0.87 V. Colorimetric analysis was conducted
using a GloMax spectrophotometer (Promega, Masison, WI, USA) recording at 450 nm using TMB
reagent released though the waste port of the assay cell.
2.3. Assay in Plasma
The assays conducted under plasma sample matrix were performed using the same protocol
applied to standard assays in PBS with the exception that IFNγ standards were diluted into plasma.
2.4. Assay Boards
Assay boards were fabricated through standard commercial PCB manufacture techniques.
A 500 µm thickness flame retardant-class 4 (FR-4) laminate cladded on both sides with 35 µm thick
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copper layers was used for the two-layer PCB. The chemically etched copper structures on the PCB
were gold plated in a second phase of the process. The solder mask layer on both sides of the boards
assured the planarisation of the device to facilitate the PMMA-based in-house microfluidic integration.
The gold plated assay surface was approximately 100 × 5 mm and the fluidic cell was approximately
100 µL in volume. The electrochemical cell consisted of three gold working electrodes, one Au counter
electrode and a Ag/AgCl reference electrode. Cells were formed over the PCB surface using PMMA
etched using a laser cutter (Epilog Helix, Epilog, UK) operating at 50% power and 60% speed, with two
etching passes across the surface.
2.5. The 16-Channel Bio-Instrumentation Board
All electrochemical measurements have taken place using the 16-channel bioinstrumentation
platform firstly shown in [50,52], where the technical characteristics of the instrument are mentioned
in detail. The overall design of the board revolves around the idea of immediate digitisation of the
sensitive analogue sensor signals [56], process them by means of standard digital signal processing
techniques and subsequently present the results to the user in digital form, either to a PC or to the
embedded on-board TFT touch screen. Due to its low power consumption, the instrument can be
battery-operated, enhancing its portability inside and outside the laboratory environment.
3. Results and Discussion
We require electrochemical detection using components manufactured by standard commercial
processes, thus, our electrode compositions and structures are considerably less refined than those
employed in general electrochemical practice and represent a novel step in the development
of PCB-based electrochemical reporter systems. In consideration of the practicability of our
electrochemical reporter systems in terms of material and subsequent signal stability, we have initially
investigated the effect of two different types of electrochemical buffers upon our system’s performance.
The first type of electrochemical buffer included chloride ions (PBS), while in the second one chloride
compounds were excluded (HEPES). Figure 1A shows an indicative data trace (amperometric signal
recorded by our in-house electronics) from a gold plated PCB-based sensing pad, generated by our
bespoke graphical user interface (GUI). In this case, an electrochemical buffer that include chloride
ions has been employed, leading to the high-current response shown in Figure 1A. More specifically,
in phase 1 (S’) the signal is stable because the thin gold electrode surface has yet to corrode through
to the underlying copper primer. In phase 2 (U’) the gold electrode surface is actively corroding as
a secondary electrochemical cell is set up at the exposed interface of the Au electrode surface and
the copper primer. In phase 3 (S”) sufficient surface area of copper primer has been exposed that
electrochemical activity associated with the copper surface is now interacting with the buffer rather
than the remaining gold electrode. While manually controlling the fluidic, assay, and electrochemical
reporter processes stability deviations were easily observed and avoided, these advantages are not
available in a fully automated system.
Figure 1B,D compare microscopy of electrodes that have demonstrated the high current phase
(Figure 1B) with chloride ions in the buffer (PBS) to that of electrodes that have only been used
with HEPES buffer (Figure 1D). Corrosion is clearly visible in the first case whereas we see only
dehydrated buffer crystals in the second. The inclusion of a chloride ion and an oxidation source has
been shown to lead to the reduction and resulting dissolution of gold surfaces [57]. Consideration of
relevant reduction potentials demonstrates that if Au and Cu are electrically connected and exposed
to electrolyte they can form a secondary electrochemical system with reduction occurring at the Au
surface while Cu is oxidised. We observe damage to the Au electrode surface and under microscopic
analysis we reveal exposed copper (Figure 1B).
Both gold and copper are able to form compounds that appear green in colour, gold(IV) chloride
and copper(I) chloride (white solid) appears green when contaminated with small amounts of the
light brown copper(II) chloride [57]. We assessed solubility and demonstrated minimal dissolution
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of the green compound in water, and following addition of iron (II) oxide we failed to generate a
precipitate. Gold chloride is more readily soluble in water than copper chloride, furthermore a solution
of gold chloride will precipitate elemental gold on addition of iron (II) oxide while copper chloride will
not [57]. Either situation would indicate dissolution of gold at the electrode surface. Our results and
observations are consistent with an active process dissolving the gold electrode surface, as unconnected
working electrodes in an active cell do not corrode (Figure 1C).
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follow ng extended electrochemistry with chloride ion containi g solutio ; (C) Unused electrode
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3.1. Demonstration of Electrochemical H2O2 Measurement
Figure 1 demonstrates that the use of non-chloride containing solutions, should allow for a more
reliable measurement system, operating at lower current ranges. Some variability due to noise is
inevitable in a solid-liquid interface electrochemical cell especially when molecular surface interaction
times have been reduced to establish optimal practical functionality. We calculated mean values
within each 100 measurement counts across areas of variable noise and we found these averages to be
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highly consistent thus we conclude that the observed noise does not affect accuracy in measurements.
Reproducibility is demonstrated by the generation of numerous H2O2 concentration measurement
curves. Ten curves are shown in Figure 2A,B detailing H2O2 concentrations between 0.375 and 12 mM
and associated electrochemical measurements. The obtained results are consistent and reproducible in
the 0–4 mM H2O2 concentration range, while at higher molarities the signal becomes marginally more
variable. The delivered range for the commercial standard TMB colorimetric assay begins with H2O2
at approximately 6.4 mM, as defined by H2O2 concentrations in standard phosphate citrate buffer
tablets (Cat#79379, Sigma-Aldrich). We conclude that our system will provide a working assay for
H2O2 without altering concentrations in current industry standard colorimetric assay protocols.
We also assessed between sensor reproducibility by applying a single H2O2 sample set to
fourteen individual sensors. We demonstrate a co-efficient of variation of 0.095, which corresponds to
approximately 10% variability (Figure 2C). We are able to calibrate signals from multiple sensors by
analysis of a fixed concentration calibration reagent and adjust our numerical output accordingly. In a
fully commercial device this could occur at the software level and the device will output values
following internal calibration, which is a standard procedure in the majority of laboratory and
field sensing devices. The described measurements were taken using 10 mM HEPES containing
various concentrations of H2O2. As H2O2 is the only variable we conclude that these measurements
are characteristic of our desired PoC sensor output and allow us to loosely predict the values or
value patterns that should be returned when measuring H2O2 in other solute matrices. We use this
performance pattern as a means to compare and characterise performance in other, more complex
solute environments.
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3.2. TMB Measurement Protocol Is Determined by H2O2 Depletion Kinetics
Our full in-line assay system consists of an assay region and electrochemical cell at the surface of a
bespoke PCB, shown in Figure 3. The assay area consists of a strip of deposited gold enclosed beneath
a PMMA cover, laser etched to create a microfluidic channel across the gold surface. Microfluidic ports
allow sample inflow and egress. During the assay phase sample is moved out of the assay area to a
waste channel (see Figure 3B). During the TMB reagent application step the channel is switched to
allow flow into an electrochemical cell consisting of Ag/AgCl reference electrode, Au counter electrode,
and three Au working electrodes that can operate either together or independently depending on
connections (as shown in Figure 3C).
Figure 4 shows amperometric assessment of H2O2 compared to colorimetric assessment of TMB
product. These analyses were performed on the same samples (following addition of 0.1 × Vol. 1 M
H3PO4). Standard product concentrations were defined by reaction time. During the reporter phase
of the assay H2O2 is a required co-factor in the conversion of TMB by the HRP enzyme. As such,
H2O2 depletion can be used to determine HRP concentration. In the standard IFNγ release ELISA
quantitation is performed colorimetrically as determined by concentration of TMB product, which is
established according to HRP concentration. Therefore, IFNγ concentration is also measurable through
H2O2 quantitation.
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Figure 3. (A) Full PCB assay and electrochemistry board showing 8 independent assay areas
(long gold strips) and 8 independent electrochemical cells (dashed line highlights a single unit cell);
(B) A three-dimensional graphical representation of the unit cell fluidic arrangement during the initial
phase of the assay; (C) A three-dimensional graphical representation of the unit cell fluidic arrangement
during the second phase of the assay, detailing fluidic ports and connections between assay area and
electrochemical sensor; (D) Detail of the biosensor’s electrical connections at the bottom of the PCB.
More specifically, in Figure 4A,B we sho ho changes in colorimetric signal correspond to
changes in H2O2 concentration using our amperometric det ction system. Our results confir t HRP
concentrati n may be qu ntified both by progressive H2O2 depletion ver time, and by in t al H2O2
depletion. To demonstrate consistency i H2O2 depletion as TMB substrate conversion progresses we
produced a similar series of measurements detailing H2O2 depletion in the presence of a very low
concentration of HRP enzyme (Figure 4C).
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Amperometric H2O2 measurements reach saturation when all available H2O2 is depleted,
after approximately 20 min (Figure 4A), while TMB product saturation only starts to become evident
at 30 min (Figure 4B). As H2O2 is a required co-factor for TMB conversion its depletion from the
electrolyte will be evident before the appearance of the associated TMB product. Therefore, rather than
allowing static incubation in an assay chamber we used a continuous flow-through arrangement
in a microfluidic assay chamber. This is beneficial both in light of the observations we have made
concerning H2O2 depletion kinetics and with respect to device functionality. The new system allows
us to flow reporter reagents directly through the assay chamber to the electrochemical detection cell,
eliminating the need for complex and laborious time-consistency steps.
To accurately quantify H2O2, measurement must be optimised in accordance with enzyme H2O2
uptake kinetics. To measure the rate of depletion of H2O2 in solution we can incubate a TMB/H2O2
reagent sample in an assay well for a certain period of time. However, in colorimetric measurements
it is possible to stop the samples from further enzymatic conversion by rapidly reducing pH. This is
not an option in electrochemical assessment as the added acid provides an electrochemical signal that
dwarfs that of H2O2 at relevant concentrations, thus, obscuring accurate quantification. This means
that added precautions must be taken to ensure that all samples develop for precisely the same amount
of time in order for them to be quantitatively comparable. For this reason, we use immediate H2O2
uptake to assess HRP concentrations.
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the assay surface would effe tively amplify differences in H2O2 co sumption due to increased reaction
times, therefore, improving th pr cision f our assay system. Either sy tem i practicable using the
same device architecture.
ti i f t t t it t f i fl t i
ti i ti t t i t tilit f i f t i l i f iff t
ti - ti i . his is i l i ifi t f t f f t i i t t i
intended for rapid multiplexed analysis of entire diagnostic biomarker suites by splitting a single
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inducted sample into multiple flow channels and thus multiple assay environments. We further
demonstrate a very detailed signal resolution confirming adequate system sensitivity. By applying
a very low HRP concentration we stretched the reaction across more than 2 h and found returned
amperometric values remained consistent with the faster reactions we have shown (Figure 4C).
3.3. Prototype IFNγ PoC Detection Assay Demonstration
TMB reagent additions were performed through a microfluidic flow cell, flowing TMB substrate
solution continuously over the assay surface and directly into the electrochemical measurement cell
without arresting delivery. Figure 5A shows a curve generated following full IFNγ assay chemistry on
a gold assay surface, detailing IFNγ concentrations titrated from 16–2048 pg/mL. Using the same assay
protocol, we show three repetitions of three samples of different IFNγ concentration measured using
the same sensor (Figure 5B). Given negligible demonstrated within sensor variabilities, this experiment
provides a measure of reproducibility of assay chemistry within our prototype system. We show
acceptable sample grouping and standard error. We also ran a number of samples in plasma matrix,
which show consistency with the analyte-spiked buffer titrations demonstrating that the system is
functional using the required medical sample matrix.
Finally, we show an automated assay performed under microfluidic flow. User input, consisting
of changing sample syringes and starting/stopping flow, was confined to operation of a syringe pump
and switching between waste and electrochemical cell outputs from the assay cell. Due to limited
numbers of sensor and assay boards we were not able to produce numerous repetitions of the following
quantifications. However, the reproducibility and statistical variance of each component of the system
has been investigated thoroughly. The following end to end assay runs demonstrate the capability of
the automation scheme we have employed and the potential to significantly reduce assay times to
PoC-relevant periods.
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We show excellent reproducibility of repeated analyses of IFNγ samples at 325 and 108 pg/mL,
and these samples fall neatly between positive and negative controls representing 10 mM HEPES
(negative control) and fresh TMB reagent containing 8 mM H2O2 (Figure 5C).
Having defined the working parameters of a full in-line assay and reporter system we generated
data to demonstrate the functionality of a complete end to end flow-through assay prototype.
We show an adequate correlation between amperometric signal and supplied IFNγ concentration
(in log2 titration series) within a full sigmoid curve showing signal extinction at low concentrations,
a linear response region, and signal saturation at high concentration. Our limit of detection (LoD),
conservatively approximated at 40 pg/mL, is broadly similar to the published R + D systems
colorimetric limit of detection (15 pg/mL) given the full range of the assay (15–2000 pg/mL) and our
own analysis of the R + D systems kit (24 pg/mL), and falls cleanly within the medically relevant IFNγ
range in TB diagnosis by IGRA. We further confirmed the accuracy of our results by running IFNγ
spiked plasma samples at four distinct concentrations and comparing them to our curve. Estimates of
concentration are approximately 93–97% accurate (see Table 1). This analysis shows that our in-line
assay prototype is functional and appropriate to purpose with respect to IFNγ quantitation in blood
plasma for clinical TB diagnosis by IGRA.
Table 1. Assayed IFNγ spiked serum samples were compared to a calibration curve from IFNγ titrated
in buffer to indicate the accuracy of clinical measurements. Percentage difference using the fit equation:
f (x) = a
(1+exp(−b x)+c) + c ranges between 3–7%.
Sample (pg/mL) Predicted Value (nA) Measured Value (nA) |%Difference|
50 157.610 149.260 5.300
100 141.560 132.340 6.510
200 97.370 104.120 6.920
300 93.680 96.620 3.130
Mean difference: 5.465%
Variability is derived from additive effects of mechanical handling, assay chemistry,
electrochemical analysis, including different assay surfaces and different electrochemical sensors.
Essentially this analysis represents the reproducibility of the full prototype system. Our results show
good grouping appropriate for IFNγ quantitation. A final working device will eliminate the largest
source of variability (between sensors) through device calibration. Values are shown in Table 2.
Table 2. Three repeats of each of three sample concentrations were measured using the prototype assay
system to demonstrate the combined variability of the full assay system.
Repeat 50 pg/mL 200 pg/mL 400 pg/mL
1 0.326 0.264 0.222
2 0.325 0.294 0.236
3 0.317 0.277 0.215
mean 0.323 0.278 0.224
Standard deviation 0.005 0.015 0.010
Coefficient of variation 0.015 0.054 0.045
The device design exploits microfluidic technology to eliminate molecular diffusion requirements
and dramatically reduce assay incubation times. Our final analysis once again uses identical assay
component concentrations but we have completely eliminated the incubation steps. Our assay required
~3 min for analyte (IFNγ) flow (100 µL/min), ~3 min for Streptavidin-HRP flow (100 µL/min),
and ~2 min for TMB flow (100 µL/min). Electrochemical readings must be taken immediately due to
enzyme H2O2 uptake kinetics described above. Discounting minimal handling times, the entire PoC
assay was therefore achieved in roughly 8 min. Finally, Table 3 summarises our system’s quantitative
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performance and compares it to other, indicative, state-of-the-art IFNγ detection systems, each one
exploiting a different detection method and fabrication materials.
Table 3. Indicative, state-of-the-art IFNγ-detection systems, utilising different methods and materials.
Ref. Detection Limit (pg/mL) Detection Range (pg/mL) Method/Materials
[58] 3.4 5–1000 Impedance immunosensor/Paper-based.
[59] 0.4 0.4–40 Square wave anodic stripping voltammetry/MNPs& AuNPs.
[60] 0.048 0.1–10,000 PDDA/AuNPs.
[61] 1.3 1.3–210 Amperometry/GO & structure-switching aptamers.
[62] 520 1000–5000 Label-free EIS/Au IDE.
This work 40 16–2048 Amperometry/PCB.
4. Conclusions
We demonstrated an integrated biosensor system capable of detection of IFNγ for use in standard
TB diagnosis by IFNγ release assay for PoC purposes. This is only one application as our innovations
apply primarily to reporter compound detection (TMB/H2O2), thus, with suitable assay conversion
can be applied to the majority of current TMB-based colorimetric analyses. We have demonstrated
performance and variability within each system component to include measurement of TMB conversion
by HRP via H2O2 depletion and antibody binding-based detection and measurement of IFNγ.
Furthermore, we have investigated within and between sensor variations and demonstrate these
to be comparable to traditional commercial systems. Finally, we have shown the working prototype,
reporting limits of detection and precision comparable to current industry standard analyses and
other indicative portable IFNγ detection systems and we show the entire assay process is possible
within eight min. Future work will revolve around extensive testing, in confirmation of results herein
with statistically significant sample population sizes and for analysis of real clinical samples to be
demonstrated in statistically significant numbers.
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